Attralus, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.attralus.com
A Study of AT-02 in Subjects With Systemic Amyloidosis.
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Attralus, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05951049
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸OHSU (Oregon Health & Science University), Portland, Oregon, United States
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Attralus, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05521022
- Locations
- 🇺🇸
OHSU (Oregon Health & Science University), Portland, Oregon, United States
🇺🇸Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇦🇺Q-Pharm Pty Ltd, Herston, Queensland, Australia
A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
Phase 2
Completed
- Conditions
- Amyloidosis
- Interventions
- Drug: I124-AT01 only
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Attralus, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05235269
- Locations
- 🇺🇸
PET/CT Imaging of Berkeley, Berkeley, California, United States
🇺🇸PET/CT Imaging of San Jose, San Jose, California, United States
🇺🇸Northern California PET Imaging Center, Sacramento, California, United States
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Attralus, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05201911
- Locations
- 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath